Results

Total Results: 2,408 records

Showing results for "treated".

441. Increasing Access to Treatment for Opioid Use Disorder in Rural Communities Through a Virtual Clinician Training and Support Program | Agency for Healthcare Research and Quality
     www.ahrq.gov/ncepcr/about/impact-stories/increasing-access.html
     April 01, 2025 - Increasing Access to Treatment for Opioid Use Disorder in Rural Communities Through a Virtual Clinician Training and Support Program AHRQ Impact: A research team in New Mexico applied the Project ECHO© model to train rural primary care clinicians in New Mexico to provide evidence-based care for pat…

442. The Importance of Investing in Care for People with Multiple Chronic Conditions (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/professionals/prevention-chronic-care/decision/mcc/mcc_infographic_printable.pdf
     June 02, 2025 - The Importance of Investing in Care for People with Multiple Chronic Conditions INVESTING IN CARE FOR PEOPLE WITH Multiple Chronic Conditions COMMON CHRONIC CONDITIONS Depression Asthma Heart Disease Arthritis Diabetes Patients with multiple chronic conditions (MCC) have two or more chronic ill…

443. The Importance of Investing in Care for People with Multiple Chronic Conditions (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/professionals/prevention-chronic-care/decision/mcc/mcc_infographic.pdf
     June 02, 2025 - The Importance of Investing in Care for People with Multiple Chronic Conditions 0 MCC = $215 3 MCC = $1,035 5 MCC = $1,620 AVERAGE ANNUAL OUT OF POCKET EXPENDITURES RX 5 chronic conditions = 50 prescriptions 3 chronic conditions = 23 prescriptions 0 chronic conditions = 3.5 prescriptions …

444. MEASURE SUMMARY (CHIPRA Core Set Candidate Measures) - Control #: PHP-19a (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/overview/background/measures-PHP-19a.pdf
     June 02, 2025 - MEASURE SUMMARY (CHIPRA Core Set Candidate Measures) - Control #: PHP-19a Completed by: Page 1 1/4/2011 MEASURE SUMMARY CHIPRA Core Set Candidate Measures A. Control #: PHP-19a B. Measure Name: Evidence of BMI Percentile Assessment C. Measure Definition a. Numerator: Children in the denominator who …

445. Attention Deficit Hyperactivity Disorder Performance Measurement Set (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-2-attach-1.pdf
     February 01, 2012 - between the research base and clinical practice.3 A survey by Gardner, et al suggests that children treated … children who met The DSM-IV-TR criteria for ADHD had reportedly had their conditions diagnosed or been treated … consideration—Please do not cite or distribute 11 • A study by Gardner, et al suggests that children treated

446. Ptoutcsurvey (doc file)
     www.ahrq.gov/sites/default/files/wysiwyg/patient-safety/settings/hospitals/red-toolkit/ptoutcsurvey.docx
     June 02, 2025 - Definitely no Probably no Probably yes Definitely yes Did you feel that your family and you were treated

447. Measure 1, Section 2, Attachment 1 (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-88-measure-1-section-2-attachment-1.pdf
     February 01, 2012 - between the research base and clinical practice.3 A survey by Gardner, et al suggests that children treated … children who met The DSM-IV-TR criteria for ADHD had reportedly had their conditions diagnosed or been treated … between the research base and clinical practice.3 • A study by Gardner, et al suggests that children treated

448. Overview | Agency for Healthcare Research and Quality
     www.ahrq.gov/pqmp/implementation-qi/toolkit/antipsychotic/overview.html
     July 01, 2021 - Safe and Judicious Use of Antipsychotic Medications in Children and Adolescents Toolkit Overview Previous Page Next Page Table of Contents Safe and Judicious Use of Antipsychotic Medications in Children and Adolescents Toolkit Introduction Overview About the Measure Key Driver Diagrams Qua…

449. Patient Outcome Survey (mailed version (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/patient-safety/settings/hospitals/red-toolkit/ptoutcsurvey.pdf
     June 02, 2025 - Did you feel that your family and you were treated with respect?

450. 5 Tk3 P3T4-Training Slides For Prescribing Clinicians Phase 3 (doc file)
     www.ahrq.gov/sites/default/files/wysiwyg/nhguide/5_TK3_P3T4-Training_Slides_for_Prescribing_Clinicians_Phase_3.docx
     May 01, 2014 - Slide Title and Commentary Slide Number and Slide Title Slide Toolkit 3. How To Develop and Implement an Antibiogram Program Phase 3. Implementation Training Slides for Prescribing Clinicians [PRINT OUT COPIES OF THE VIGNETTES AND ANTIBIOGRAMS FOR ALL PARTICIPANTS. PASS OUT THE VIGNETTES EARLY, THEN PROVIDE THE ANTI…

451. Assess-Resident-Uti-Facilitator-Guide (doc file)
     www.ahrq.gov/sites/default/files/wysiwyg/antibiotic-use/long-term-care/assess-resident-UTI-facilitator-guide.docx
     June 01, 2021 - This means there is bacteria in the urine, but it does not need to be treated.

452. Sepsis in the ED Detailed Measure, Technical Specifications (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-228-detailed_measure-specs.pdf
     August 01, 2014 - Sepsis in the ED Detailed Measure, Technical Specifications Q-METRIC Sepsis Measure 1, ED Protocol for Children with Sepsis Syndrome U18HS020516 Page 41 Submitted August 2014 Sepsis Measure 1: Protocol for Identifying and Treating Children with Sepsis Syndrome in the Emergency Department Desc…

453. FAQs (Staff): Safety and Side Effects: CHG and Mupirocin (doc file)
     www.ahrq.gov/sites/default/files/wysiwyg/hai/abate/faqs/faq-safety-chg-mupirocin.docx
     March 01, 2022 - FAQs (Staff): Safety and Side Effects: CHG and Mupirocin Decolonization of Non-ICU Patients With Devices Section 14-6 – Addressing Questions Asked by Staff: Safety and Side Effects of Chlorhexidine and Mupirocin This hospital will be using chlorhexidine gluconate (CHG) and nasal mupirocin to reduce bacteria that c…

454. FAQs (Staff) Safety and Side Effects CHG and Iodophor (doc file)
     www.ahrq.gov/sites/default/files/wysiwyg/hai/abate/faqs/faq-safety-chg-iodophor.docx
     March 01, 2022 - FAQs (Staff) Safety and Side Effects CHG and Iodophor Decolonization of Non-ICU Patients With Devices Section 14-7 – Addressing Questions Asked by Staff: Safety and Side Effects of Chlorhexidine and Iodophor This hospital will be using chlorhexidine gluconate (CHG) and nasal iodophor to reduce bacteria that can caus…

455. Candidate Measure Submission Form (CPCF) | Agency for Healthcare Research and Quality
     www.ahrq.gov/policymakers/chipra/cpcf-form15.html
     December 01, 2013 - Medical records for all patients treated at the practice site are available to and shared by all providers

456. Best Practices in the Diagnosis and Treatment of Cellulitis and Skin and Soft Tissue Infections
     www.ahrq.gov/sites/default/files/wysiwyg/antibiotic-use/best-practices/cellulitis-slides.pptx
     November 01, 2019 - edema) Primary outcome: resolution by day 14 and no recurrence by day 28 98% of patients in both groups treated

457. PowerPoint Presentation (ppt file)
     www.ahrq.gov/sites/default/files/wysiwyg/nhguide/5_TK3_P3T4-Training_Slides_for_Prescribing_Clinicians_Phase_3.ppt
     May 01, 2014 - PowerPoint Presentation Toolkit 3. How To Develop and Implement an Antibiogram Program Phase 3. Implementation Training Slides for Prescribing Clinicians Nursing Home Antimicrobial Stewardship Guide Help Clinicians Choose the Right Antibiotic www.ahrq.gov/NH-ASPGuide ● May 2014 AHRQ Pub. No. 14-0023-5-EF [Print …

458. P12: Using a Televideo-based Training Model for Providers to Expand Treatment for Opioid Use Disorder in Rural New Mexico | Agency for Healthcare Research and Quality
     www.ahrq.gov/ncepcr/reports/2024-annual-report/profile-p12-salvador.html
     May 01, 2024 - Investments in Primary Care Research for 2021 and 2022 P12: Using a Televideo-based Training Model for Providers to Expand Treatment for Opioid Use Disorder in Rural New Mexico Previous Page Next Page Table of Contents Investments in Primary Care Research for 2021 and 2022 Acknowledgments and Auth…

459. Making the Case That Improving Antibiotic Use Is a Patient Safety Issue (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/antibiotic-use/safety/patient-safety-facilitator-guide.pdf
     November 01, 2019 - Moment 4 should occur as soon as it is clear what infectious process is being treated and the patient

460. 130. Treatment Recommendations: Medications-Bupropion | Agency for Healthcare Research and Quality
     www.ahrq.gov/prevention/guidelines/tobacco/clinicians/presentations/2008update-full/slide130.html
     October 01, 2014 - 130. Treatment Recommendations: Medications-Bupropion Treating Tobacco Use and Dependence: 2008 Update Text version of slide presentation. Patient selection Appropriate as a first-line medication for treating tobacco use Precautions, warnings, contraindications and side effects (see FDA pack…